Overview

Z-360 Plus GEM in Subjects With Metastatic Pancreatic Adenocarcinoma

Status:
Completed
Trial end date:
2017-03-01
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to compare the efficacy of GEM plus Z-360 versus GEM plus placebo on the overall survival (OS) in subjects with metastatic Pancreatic Adenocarcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Zeria Pharmaceutical
Treatments:
Gemcitabine